<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Incretin based therapies are known to have pleotropic benefits in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> but have not been studied in new <z:hpo ids='HP_0003674'>onset</z:hpo> type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>In this randomized, open label study, we investigated the effect of the addition of exenatide or <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> to insulin in patients with new <z:hpo ids='HP_0003674'>onset</z:hpo> type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Our data suggest that the addition of exenatide and <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> decreases insulin requirements without increasing endogenous insulin production and hypoglycemic events </plain></SENT>
</text></document>